SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Clarification from Glenmark Pharmaceuticals

29 Jul 2015 Evaluate

With reference to the news article in Financial Express July 29, 2015 captioned ‘Glenmark Pharmas skin gel infringes patent, says US court’, Glenmark Pharmaceuticals has clarified that they confirm the decision has been passed by the U.S. Court. Challenges in Para-IV filings are a usual practice in U.S. and the said decision can be appealed against. The Company is not generating any revenues out of the said product and hence the court decision has no material impact on the Company.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

2247.90 -1.65 (-0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×